Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Cannabis Bioscience International Holdings Gross Margin %?
Cannabis Bioscience International HoldingsCBIH +33.33% Gross Margin % is 72.73% as of Feb. 2026, which is 45% above its 10-year median of 50.00. The stock has 4 warning signs investors should review. Among 943 Drug Manufacturers companies, Cannabis Bioscience International Holdings ranks better than 90.67% on this metric.
Cannabis Bioscience International Holdings (OTCPK:CBIH) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cannabis Bioscience International Holdings had a gross margin of 72.73% for the quarter that ended in Feb. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cannabis Bioscience International Holdings Gross Margin % Related Terms
Cannabis Bioscience International Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannabis Bioscience International Holdings Gross Margin % Chart
Cannabis Bioscience International Holdings Annual Data
CBIH vs SXTC, UPC, NPHC: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannabis Bioscience International Holdings Gross Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cannabis Bioscience International Holdings (CBIH) has a Gross Margin % of 72.73% as of Feb. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Cannabis Bioscience International Holdings and its competitors. This is 45% above median its historical median of 50.00. Over the past decade, Cannabis Bioscience International Holdings' Gross Margin % has ranged from 19.47 to 86.80. According to the industry distribution chart, Cannabis Bioscience International Holdings ranks #88 out of 943 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Cannabis Bioscience International Holdings' Gross Margin % too high?
Cannabis Bioscience International Holdings' current Gross Margin % of 72.73% is 45% above median its 10-year median of 50.00. Over the past 10 years, this metric has ranged from a low of 19.47 to a high of 86.80. The Drug Manufacturers industry median Gross Margin % is 48.54. Cannabis Bioscience International Holdings' value of 72.73% is 49.8% above this industry median. Based on the distribution chart, Cannabis Bioscience International Holdings ranks #88 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cannabis Bioscience International Holdings' Gross Margin % compare to SXTC and UPC?
According to the Drug Manufacturers industry distribution chart, Cannabis Bioscience International Holdings ranks #88 out of 943 companies for Gross Margin %. This places Cannabis Bioscience International Holdings in the top 9% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Cannabis Bioscience International Holdings' value of 72.73% is 49.8% above this benchmark. Historically, Cannabis Bioscience International Holdings' own Gross Margin % has ranged from 19.47 to 86.80 over the past decade. While the company's 10-year median is 50.00 vs. the industry median of 48.54, Cannabis Bioscience International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannabis Bioscience International Holdings's current Gross Margin % of 72.73% is 49.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cannabis Bioscience International Holdings and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Bioscience International Holdings's current Gross Margin % is 72.73%, which is 45% above median its own 10-year median of 50.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Bioscience International Holdings stock overvalued right now?
Cannabis Bioscience International Holdings (CBIH) has a current Gross Margin % of 72.73%. The current Gross Margin % is 72.73%, which is 45% above median its 10-year median of 50.00 and 49.8% above the Drug Manufacturers industry median of 48.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cannabis Bioscience International Holdings (CBIH), the current Gross Margin % is 72.73% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cannabis Bioscience International Holdings Inc operates in three main areas. Firstly, the company engages in cannabis-related research and education under the trade name Pharmacology University. Secondly, it serves as both a Sponsor and a Contract Research Organization (CRO) in clinical trials, some of which involve cannabis and CBD products, under the trade name Alpha Research Institute. Lastly, the company plans to manufacture, market, and sell CBD products branded as "VitaCookies." The majority of the company's revenue comes from clinical trial contracts, while a smaller portion is generated from cannabis-related educational classes and seminars.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIH has been successfully added to your 
